Evidence map›Paper›PMID 41463479›Full record

ArticleBiology2025

Comparative Genomic and Microenvironmental Profiles of Hereditary and Sporadic TNBC in Colombian Women.

Yina T Zambrano-Ordoñez, Alejandro Mejía-Garcia, Julieta M Ramírez-Mejía, Hsuan M Tsao, Paula D Morales-Suárez, Laura Rey-Vargas, Wendy J Montero-Ovalle, Carlos A Huertas-Caro, Patricia Lopez-Correa, Julián C Riaño-Moreno and 7 more

Abstract read
In one paragraph

Article in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yina T Zambrano-OrdoñezGrupo de Investigación Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.ORCID 0009-0000-5131-602X
Alejandro Mejía-GarciaHuman Genetics Department, McGill University, Montreal, QC H3A 0G4, Canada.
Julieta M Ramírez-MejíaGrupo de Investigación Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.
Hsuan M TsaoHuman Genetics Department, McGill University, Montreal, QC H3A 0G4, Canada.ORCID 0009-0000-9442-8638
Paula D Morales-SuárezGrupo de Investigación Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.
Laura Rey-VargasGrupo de Investigación Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.ORCID 0000-0002-0706-2162
Wendy J Montero-OvalleGrupo de Investigación Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.
Carlos A Huertas-CaroGrupo de Investigación Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.ORCID 0000-0002-7962-8081
Patricia Lopez-CorreaDepartamento de Patología Oncología Molecular, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.
Julián C Riaño-MorenoDepartamento de Patología Oncología Molecular, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.
Juliana L RodriguezGrupo de Investigación Clínica y Epidemiológica, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.
Maria Carolina Sanabria-SalasGrupo de Investigación Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.
Luis G Carvajal-CarmonaDepartment of Biochemistry and Molecular Medicine, University of California Davis, Davis, CA 95616, USA.ORCID 0000-0001-7129-2918
I King JordanGeorgia Institute of Technology, Bioinformatics Department, Atlanta, GA 30332, USA.ORCID 0000-0003-4996-2203
Silvia J Serrano-GomezGrupo de Investigación Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.
Liliana Lopez-KleineDepartamento de Estadística, Universidad Nacional de Colombia, Bogotá 111321, Colombia.ORCID 0000-0001-9325-9529
Carlos A OrozcoGrupo de Investigación Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá 110111, Colombia.

Funding

The Upstream Center: Income Interventions to Address the Fundamental Causes of Cancer InequitiesU54CA280811 · NCI · STANFORD UNIVERSITY · PI MELISSA L. BONDY · 2023 to 2026
$10.8M
University of California and UT Southwestern D-PDTCU54CA283766 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Luis Guillermo Carvajal Carmona · 2023 to 2026
$5.9M
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIVR01CA260689 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHIAO, ELIZABETH Y., SILVERBERG, MICHAEL J · 2021 to 2025
$4.0M
Understanding the biology of disparity-associated genomically stable gastric tumorsR56CA280636 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARVAJAL CARMONA, LUIS GUILLERMO · 2024 to 2025
$483k
Instituto Nacional de Cancerología- Bogota Colombia C1901030045; C19990300218; C19990300210NCI NIH HHS R01 CA260689NCI NIH HHS R56 CA280636NCI NIH HHS U54 CA280811NCI NIH HHS U54 CA283766
6 · The paper itself

Abstract

Breast cancer (BC) is a heterogeneous disease, and triple-negative breast cancer (TNBC) is the most aggressive and immunogenic subtype. A significant proportion of TNBC cases are linked to hereditary cancer syndromes involving pathogenic germline variants, most commonly in

Indexed as

Colombian/Latin American populationgene expression profilinghereditary breast cancerTNBC

Identifiers

PMID41463479
PMCPMC12730083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.